The corona vaccine from the US company Novavax is in the starting blocks.
A new study gives hope that it will be highly effective.
Kassel - A new Corona * vaccine is to be approved within the European Union this year.
An accelerated test procedure has been running for the vaccine from the US company Novavax since February.
The special thing about it: The vaccine called NVX-CoV2373 would introduce a new principle of action against Sars-Cov-2, which, however, is already known in a similar way from flu vaccines.
This is because the preparation is not an mRNA vaccine, like the products from Biontech and Moderna, nor is it a vector vaccine, as in the case of Astrazeneca or Johnson & Johnson.
Instead, the active ingredient contains artificial spike proteins from the pathogen, which are produced in a laboratory - the body does not have to produce these proteins itself.
This reported the pharmacies around the world.
+
The new corona vaccine from Novavax gives hope: A vaccination should even protect 100 percent against a severe course.
© Thiago Prudencio / Imago
Corona vaccine from Novavax: Vaccination should protect 100 percent against a severe course
According to the results of a phase 3 study that Novavax published in June 2021, the vaccine has an effectiveness of 90.4 percent.
The protection against moderate to severe courses should even be 100 percent.
In addition, the test subjects tolerated the vaccination well and had no drastic side effects.
Only occasional pain at the injection site, tiredness, headache and muscle pain occurred.
The study enrolled 29,960 people in the United States and Mexico.
Back in the spring, a British study confirmed that the Novavax corona vaccine was highly effective *.
However, it is still unclear when exactly the drug will be approved in Germany.
At the beginning of August, the European Commission had already secured access to 200 million vaccine doses by 2023.
EU Commission President Ursula von der Leyen (CDU) justified the decision with the fact that the vaccine strengthens “our broad vaccine portfolio for the benefit of people in Europe and our partners worldwide”.
But the new Corona vaccine Valneva is also in the starting blocks and should even convince vaccine skeptics.
(Nail Akkoyun)
* Hna.de is an offer from IPPEN.MEDIA.
List of rubric lists: © Thiago Prudencio / Imago
